Picture loading failed.

Anti-CD3E therapeutic antibody (Pre-made Visilizumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Visilizumab (tentative trade name Nuvion, PDL BioPharma Inc.) is a humanized monoclonal antibody. It is being investigated for use as an immunosuppressive drug in patients with ulcerative colitis and Crohn's disease. Visilizumab binds to the CD3 receptor on certain activated T cells without affecting resting T cells. It is currently under clinical studies for the treatment of ulcerative colitis and Crohn's disease.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-622-1mg 1mg 3090
GMP-Bios-ab-622-10mg 10mg 21890
GMP-Bios-ab-622-100mg 100mg 148000
GMP-Bios-ab-622-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-CD3E therapeutic antibody (Pre-made Visilizumab biosimilar,Whole mAb)
INN Name Visilizumab
TargetCD3E
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG2
VD LCnd
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2000
Year Recommended2001
CompaniesPDL BioPharma
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedCrohn's disease;Graft-versus-host disease;Psoriasis;Renal transplant rejection;Ulcerative colitis
Development Techna